Status:
TERMINATED
Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
Detailed Description
This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. PSA response is the primary end-point and objective response...
Eligibility Criteria
Inclusion
- At least 18 years of age.
- Metastatic disease.
- One previous treatment including docetaxel (Taxotere).
- At least 3 weeks since last surgery/radiation/chemotherapy
- ECOG Performance Status of 0, 1 or 2
Exclusion
- Active brain metastases
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00104130
Start Date
December 1 2004
End Date
February 1 2005
Last Update
September 17 2008
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente Medical Center
Vallejo, California, United States, 94589
2
Georgia Cancer Specialists
Tucker, Georgia, United States, 30084
3
University of Maryland Medical System
Baltimore, Maryland, United States, 21201
4
Washington University School of Medicine
St Louis, Missouri, United States, 63310